IP Library Granted Patent US 11,693,017
Granted Patent B2
US 11,693,017 · App. 15/760,352 · Granted Jul 4, 2023

Small molecule biosensors

Inventors: Daniel J. Mandell (Brookline, MA); Justin Feng (Cambridge, MA); Xavier Rios Villanueva (Boston, MA); Rajagopal Chari (Brighton, MA)
Assignee: President and Fellows of Harvard College
G01N33/743C07K14/00C12N9/22C12N15/11C12N15/62C12N15/63C12N15/902C07K2319/00C12N2310/20C12N2320/50C12N2800/22C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,693,017
App. No.
15/760,352
Granted
Jul 4, 2023
Kind
B2
Abstract

Biosensors for small molecules can be used in applications that range from metabolic engineering to orthogonal control of transcription. Biosensors are produced based on a ligand-binding domain (LBD) using a method that, in principle, can be applied for any target molecule. The LBD is fused to either a fluorescent protein or a transcriptional activator and is destabilized by mutation such that the fusion accumulates only in cells containing the target ligand. The power of this method is illustrated by developing biosensors for digoxin and progesterone. Addition of ligand to cells expressing a biosensor activates transcription in yeast, mammalian cells and plants, with a dynamic range of up to about 100-fold or more. The biosensors are used to improve the biotransformation of pregnenolone to progesterone in yeast and to regulate CRISPR activity in mammalian cells. This work provides a general methodology to develop biosensors for a broad range of molecules.

Claims (9)

1. A conditionally stable biosensor comprising a homodimeric ligand binding domain (LBD) having conditionally-destabilizing mutations that is fused to a trans-activation domain (TAD) and a DNA binding domain (DBD), wherein the conditionally stable biosensor is stabilized when the ligand binding domain is bound to a cognate steroid, and wherein the DNA binding domain (DBD) binds to DNA and the trans-activation domain (TAD) activates transcription of a target gene.

2. The conditionally stable biosensor of claim 1 , wherein the conditionally stable biosensor retains function when ported directly between yeast and mammalian cells.

3. The conditionally stable biosensor of claim 1 , wherein the ligand binding domain is between an N-terminal DNA binding domain and a C-terminal transcriptional activation domain.

4. The conditionally stable biosensor of claim 1 , wherein the ligand binding domain binds to digoxigenin.

5. The conditionally stable biosensor of claim 1 , wherein the ligand binding domain binds to progesterone.

6. The conditionally stable biosensor of claim 1 , wherein the trans-activation domain (TAD) is VP16.

7. The conditionally stable biosensor of claim 1 , wherein the trans-activation domain (TAD) is VP64.

8. A cell line comprising the conditionally stable biosensor of claim 1 .

9. The conditionally stable biosensor of claim 1 wherein the DNA binding domain (DBD) is a homodimeric DNA binding domain (DBD).

Assignments (3)
CONFIRMATORY LICENSE Recorded Nov 22, 2019
From: HARVARD UNIVERSITY
To: UNITED STATES DEPARTMENT OF ENERGY
Reel/Frame 051097/0370 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2019
From: CHARI, RAJAGOPAL; FENG, JUSTIN; MANDELL, DANIEL J.; RIOS VILLANUEVA, XAVIER
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 047892/0169 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2018
From: CHARI, RAJAGOPAL; FENG, JUSTIN; MANDELL, DANIEL J.; RIOS VILLANUEVA, XAVIER
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 047832/0315 →
Continuity (2)
Provisional Application 62220628 · Sep 18, 2015
Related Publication 20180259541A1 · Sep 13, 2018